Tarsus Pharmaceuticals, Inc. (TARS)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Tarsus Pharmaceuticals, Inc. reported revenue of $451.36M, up 146.7% from the prior year. The company ran a net loss, with a net margin of -14.7%. It held $562.16M in total assets against $218.73M in total liabilities.
Key ratios (FY2025)
-15.7%
Operating margin
-14.7%
Net margin
-19.3%
Return on equity
+146.7%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $451.36M | $182.95M | $17.45M | $25.82M | $57.03M | $0 | — | — | — |
| Operating Income | -$70.97M | -$120.57M | -$143.16M | -$62.71M | -$12.16M | -$27.00M | -$4.30M | — | — |
| Net Income | -$66.42M | -$115.55M | -$135.89M | -$62.09M | -$13.83M | -$26.81M | -$4.67M | -$1.32M | — |
| EPS (Diluted) | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 | $-4.32 | — | — | — |
| Total Assets | $562.16M | $376.99M | $265.49M | $227.86M | $178.91M | $171.97M | $58.32M | — | — |
| Total Liabilities | $218.73M | $152.46M | $68.50M | $34.96M | $12.18M | $5.99M | $919.0K | — | — |
| Shareholders' Equity | $343.43M | $224.53M | $196.99M | $192.90M | $166.73M | $165.98M | -$6.00M | -$1.35M | -$44.0K |
| Cash & Equivalents | $183.64M | $94.82M | $224.95M | $71.66M | $171.33M | $168.13M | $57.95M | — | — |
| Operating Cash Flow | -$12.45M | -$83.03M | -$117.49M | -$49.03M | $3.75M | -$21.14M | -$3.67M | — | — |
| Capital Expenditures | $9.86M | $1.57M | $1.50M | $506.0K | $586.0K | $456.0K | $175.0K | — | — |
| Shares Outstanding | 42.55M | 38.35M | 34.21M | 26.70M | 20.70M | 20.32M | 2.65M | — | — |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |